Q3 2025 Management View CEO Joseph Payne reported that interim Phase II data for ARCT-032, the company’s mRNA therapeutic candidate for cystic fibrosis (CF), showed "treatment with inhaled ...
Supportive therapy, like medications to help open the airways and heal infections, can help you live a healthier life and meet many of the challenges of this inherited respiratory condition. Share on ...
EXCLUSIVE: The Express has campaigned for cystic fibrosis sufferers for six years but now a charity is highlighting the CF ...
Cystic fibrosis (CF) therapeutics refer to treatments designed to manage and alleviate the symptoms of cystic fibrosis, a ...
Modulator therapy does not appear to affect the magnitude of lung function impairment or recovery pattern during pulmonary ...
Over the course of two decades spent developing treatments for the genetic lung disease cystic fibrosis, biologist Fredrick Van Goor has had hundreds of conversations with patients. But he remembers ...
Alyftrek (vanzacaftor/tezacaftor/deutivacaftor) is a combination medicine approved by the FDA in 2024. Alyftrek is approved to treat people ages 6 and older who have ...
Discover why Sionna Therapeutics stock may offer upside, driven by a strong cash position and key cystic fibrosis clinical ...
Vertex Pharmaceuticals Inc. reported third-quarter sales that beat analysts’ expectations as the biotech company’s mainstay ...
5don MSN
INTERVIEW: ‘Surf Shop Shootout’ surf competition to raise money for those with cystic fibrosis
The Live Fearless Foundation is holding its 4th annual Surf Shop Shootout, a surf contest benefiting those with the genetic ...
Brensocatib, a DPP1 inhibitor, is the first FDA-approved therapy for non-cystic fibrosis bronchiectasis, showing significant clinical and structural benefits. The ASPEN trial demonstrated that ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback